These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 25428414

  • 1. Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1.
    Shiotani A, Kusunoki H, Ishii M, Imamura H, Manabe N, Kamada T, Hata J, Merchant JL, Haruma K.
    Neurogastroenterol Motil; 2015 Jan; 27(1):82-91. PubMed ID: 25428414
    [Abstract] [Full Text] [Related]

  • 2. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
    Fukudo S, Kinoshita Y, Okumura T, Ida M, Akiho H, Nakashima Y, Nishida A, Haruma K.
    Gastroenterology; 2016 Feb; 150(2):358-66.e8. PubMed ID: 26551550
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ, Kim NY, Kwon JK, Huh KC, Lee OY, Lee JS, Choi SC, Sohn CI, Myung SJ, Park HJ, Choi MK, Bak YT, Rhee PL.
    Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
    [Abstract] [Full Text] [Related]

  • 4. Abnormalities of mucosal serotonin metabolism and 5-HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron.
    Gunn D, Garsed K, Lam C, Singh G, Lingaya M, Wahl V, Niesler B, Henry A, Hall IP, Whorwell P, Spiller R.
    Aliment Pharmacol Ther; 2019 Sep; 50(5):538-546. PubMed ID: 31342534
    [Abstract] [Full Text] [Related]

  • 5. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
    Fukudo S, Matsueda K, Haruma K, Ida M, Hayase H, Akiho H, Nakashima Y, Hongo M.
    Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
    [Abstract] [Full Text] [Related]

  • 6. Identification of a functional TPH1 polymorphism associated with irritable bowel syndrome bowel habit subtypes.
    Grasberger H, Chang L, Shih W, Presson AP, Sayuk GS, Newberry RD, Karagiannides I, Pothoulakis C, Mayer E, Merchant JL.
    Am J Gastroenterol; 2013 Nov; 108(11):1766-74. PubMed ID: 24060757
    [Abstract] [Full Text] [Related]

  • 7. Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome.
    Katsumata R, Shiotani A, Murao T, Ishii M, Fujita M, Matsumoto H, Haruma K.
    Intern Med; 2017 Nov; 56(9):993-999. PubMed ID: 28458330
    [Abstract] [Full Text] [Related]

  • 8. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
    Qi Q, Zhang Y, Chen F, Zuo X, Li Y.
    BMC Gastroenterol; 2018 Jan 08; 18(1):5. PubMed ID: 29310568
    [Abstract] [Full Text] [Related]

  • 9. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D.
    Scand J Gastroenterol; 2008 Jan 08; 43(10):1202-11. PubMed ID: 18618371
    [Abstract] [Full Text] [Related]

  • 10. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis.
    Yu FY, Huang SG, Zhang HY, Ye H, Chi HG, Zou Y, Lv RX, Zheng XB.
    World J Gastroenterol; 2016 Mar 28; 22(12):3451-9. PubMed ID: 27022227
    [Abstract] [Full Text] [Related]

  • 11. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
    Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K.
    Clin Gastroenterol Hepatol; 2014 Jun 28; 12(6):953-9.e4. PubMed ID: 24315882
    [Abstract] [Full Text] [Related]

  • 12. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.
    Fukudo S, Kinoshita Y, Okumura T, Ida M, Hayashi K, Akiho H, Nakashima Y, Haruma K.
    J Gastroenterol; 2016 Sep 28; 51(9):874-82. PubMed ID: 26800997
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Association of Fatigue With TPH2 Genetic Polymorphisms in Women With Irritable Bowel Syndrome.
    Han CJ, Jarrett ME, Cain KC, Jun S, Heitkemper MM.
    Biol Res Nurs; 2019 Jan 28; 21(1):72-79. PubMed ID: 30309244
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Effects of baldrinal of Valeriana jatamansi on expression of CRF, TPH1 mRNA and 5-HT in rats with irritable bowel syndrome].
    Tao SY, Xiao CR, Wang J, Zhang SJ, Gao YS, Mu FY, Wang YC, Yan XL.
    Zhongguo Zhong Yao Za Zhi; 2017 Jan 28; 42(2):347-351. PubMed ID: 28948742
    [Abstract] [Full Text] [Related]

  • 19. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D.
    Digestion; 2008 Jan 28; 77(3-4):225-35. PubMed ID: 18667823
    [Abstract] [Full Text] [Related]

  • 20. S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome.
    Shiotani A, Kusunoki H, Kimura Y, Ishii M, Imamura H, Tarumi K, Manabe N, Kamada T, Hata J, Haruma K.
    Dig Dis Sci; 2013 Aug 28; 58(8):2314-23. PubMed ID: 23595519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.